Key terms
About SLGL
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SLGL news
Apr 01
7:57am ET
Sol-Gel Announces Generic Drug Application for Psoriasis Treatment
Apr 01
7:18am ET
Sol-Gel Technologies collaboration partner first-to-file ANDA generic to Zoryve
Mar 13
7:16am ET
Sol-Gel Technologies sees cash runway into 2H25
Mar 13
7:16am ET
Sol-Gel Technologies reports 2023 EPS ($1.01) vs. (65c) last year
No recent press releases are available for SLGL
SLGL Financials
Key terms
Ad Feedback
SLGL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SLGL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range